European vaccine hub founded: new impulses for panda control!

European vaccine hub founded: new impulses for panda control!

Siena, Italien - On May 22nd and 23rd, 2025, the opening event of the European Vaccines Hub for Pandemic Readiness (EVH) in Siena, Italy, took place. This important project is coordinated by the Italian NPO Sclavo Vaccines Association and combines 11 institutions and organizations from 7 countries. The aim is to develop new vaccines for public health in order to be able to counter pandemic challenges more effectively. As reported as uni-marburg.de , the EVH project will be European Executive Agency for Health and Digital (Hadea) supported.

The EVH program is divided into four essential columns: The first pillar "Discovery" is led by the Fondazione Biotecnopolo di Siena, followed by "preclinical studies" under the direction of the Institute Pasteur in France. Vaccinopolis at the University of Antwerp is responsible for clinical studies, while the fourth pillar that addresses the manufacture is coordinated by the German Center for Infection Research (DZIF). This structured approach is intended to ensure that all steps from research to clinical studies to production are efficiently covered.

financing and international cooperation

The EVH project receives support of around 102 million euros via the EU4Health program, with an estimated total project costs of around 170 million euros. An important part of this financing - around 21 million euros - goes to German institutions that work under the roof of the DZIF. The cooperation between the many partners involved, including well -known European organizations and research institutes, is essential for the success of the project.

The organizations involved include the Center for Pandemie Vaccines and Therapeutics (Zepai) at the Paul-Ehrlich-Institut in Germany and the Norwegian Institute of Public Health (Nip) from Norway. The Instituto de Biologia Experimental e Tecnológica (Ibet) from Portugal and the Université Libre de Bruxelles from Belgium are also partners. The DZIF leads the column in terms of manufacture and regulation and is involved in almost all work packages.

vaccine development in the global context

The development of vaccines has a long history that goes back to the 16th century. According to vaccination-info.europa.eu began to research mna technology in the 1960s. It was not until 2020 that the first MRNA vaccine against Covid-19 was approved in Europe and thus standardized modern vaccine development.

The advantages of the mRNA vaccines are versatile: they enable a quick adaptation to new virus variants and do not require adjuvanzia, which means that they are also suitable for immunosuppressed patients. In the future, modular production facilities, such as bionainers, could significantly simplify local vaccine production. In addition, research shows promising approaches to the use of DNA vaccines that are more stable and easier to manufacture. However, they are currently still in the test phase, since their security and effectiveness have to be demonstrated before they can be approved in the EU.

The way to the future

with the help of the EVH and the innovative approaches of modern vaccine technology, a fundamental improvement in global health care is sought. The search for new solutions in vaccine development, adaptation to pandemic threats and cooperation at the international level are of crucial importance today. Not only is the fight against current infectious diseases, but also the prevention of cancer by vaccinations, which according to pmc.nlm.nih.gov moves.

The combination of traditional immunology and innovative approaches such as mrNA and DNA technology will revolutionize the landscape of vaccine development and has the potential to manage future health crises more effectively.